Hong YS, Kim SY, Lee JS, et al. - In the ADORE trial (adjuvant oxaliplatin in rectal cancer), a multicenter, randomized trial in individuals with postoperative ypStage II (ypT3-4N0) or III (ypT_anyN1-2) rectal cancer following fluoropyrimidine-based preoperative chemoradiotherapy (CRT) and total mesorectal excision (TME), experts assessed the role of oxaliplatin as adjuvant chemotherapy in people with rectal cancer who received preoperative CRT with fluoropyrimidine monotherapy and TME. Between November 19, 2008, and June 12, 2012, 321 people were recruited. In individuals with rectal cancer with ypStage II and III disease, adjuvant FOLFOX enhanced disease-free survival following preoperative CRT. Thus, in those who received preoperative CRT and TME, adjuvant FOLFOX may be recognized based on the postoperative pathologic stage.